ES2634204T3 - Composición farmacéutica que comprende derivados de piridona - Google Patents

Composición farmacéutica que comprende derivados de piridona Download PDF

Info

Publication number
ES2634204T3
ES2634204T3 ES12740018.2T ES12740018T ES2634204T3 ES 2634204 T3 ES2634204 T3 ES 2634204T3 ES 12740018 T ES12740018 T ES 12740018T ES 2634204 T3 ES2634204 T3 ES 2634204T3
Authority
ES
Spain
Prior art keywords
dementia
group
cognitive
disorder
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12740018.2T
Other languages
English (en)
Spanish (es)
Inventor
Cheol Young Maeng
Young Koo JANG
Su Bong CHA
Hye Won Shin
Chan Mi Joung
Hwa Ryun CHA
Eun Jung Yi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SK Biopharmaceuticals Co Ltd
Original Assignee
SK Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SK Biopharmaceuticals Co Ltd filed Critical SK Biopharmaceuticals Co Ltd
Application granted granted Critical
Publication of ES2634204T3 publication Critical patent/ES2634204T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C07D453/04—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems having a quinolyl-4, a substituted quinolyl-4 or a alkylenedioxy-quinolyl-4 radical linked through only one carbon atom, attached in position 2, e.g. quinine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES12740018.2T 2011-01-28 2012-01-30 Composición farmacéutica que comprende derivados de piridona Active ES2634204T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20110008960 2011-01-28
KR20110008960 2011-01-28
PCT/KR2012/000648 WO2012102580A1 (en) 2011-01-28 2012-01-30 Pharmaceutical composition comprising pyridone derivatives

Publications (1)

Publication Number Publication Date
ES2634204T3 true ES2634204T3 (es) 2017-09-27

Family

ID=46581019

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12740018.2T Active ES2634204T3 (es) 2011-01-28 2012-01-30 Composición farmacéutica que comprende derivados de piridona

Country Status (8)

Country Link
US (1) US8716309B2 (https=)
EP (1) EP2668186B1 (https=)
JP (1) JP5921576B2 (https=)
KR (1) KR101925971B1 (https=)
CN (1) CN103328477B (https=)
CA (1) CA2824467C (https=)
ES (1) ES2634204T3 (https=)
WO (1) WO2012102580A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101928505B1 (ko) 2011-01-28 2018-12-12 에스케이바이오팜 주식회사 피리돈 유도체 및 이를 포함하는 약학적 조성물
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
MX382781B (es) 2014-04-02 2025-03-13 Intermune Inc Piridinonas anti-fibroticas.
EP3259262A4 (en) * 2015-02-17 2018-08-01 Mapi Pharma Limited Process and intermediates for the preparation of perampanel
AR107928A1 (es) 2016-03-22 2018-06-28 Merck Sharp & Dohme Moduladores alostéricos de receptores de acetilcolina nicotínicos
WO2019028062A1 (en) * 2017-07-31 2019-02-07 Washington University PIRFENIDONE DERIVATIVES FOR MODULATION OF B-LYMPHOCYTE ACTIVITY AND PROTECTION OF ORGANS
RS66290B1 (sr) 2018-05-01 2025-01-31 Merck Sharp & Dohme Llc Spiropiperidin alosterični modulatori nikotinskih acetiholinskih receptora
CN109293507B (zh) * 2018-10-12 2020-12-18 河北科技大学 4-甲氧基甲烯基-2-烯戊二酸二甲酯的合成方法及其应用
EP4054569A4 (en) 2019-11-05 2023-10-25 Merck Sharp & Dohme LLC ALLOSTERIC SPIROPIPERIDINE MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4404138A (en) * 1982-06-22 1983-09-13 Warner-Lambert Company 3-[2-(Azabicyclo) ethyl]-1,2,3,4-tetrahydro-5H-[1]benzopyrano[3,4-c]pyridin-5-ones
TR200102162T2 (tr) * 1999-01-29 2001-12-21 Abbott Laboratories Nikotinik asetilkolin reseptör ligandları olarak diazabisiklik türevler.
SE0000540D0 (sv) * 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
US6569865B2 (en) * 2001-06-01 2003-05-27 Astrazeneca Ab Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine
AU2002339810A1 (en) * 2001-10-16 2003-04-28 Astrazeneca Ab Azabicyclic compounds for the treatment of fibromyalgia syndrome
FR2834511B1 (fr) * 2002-01-07 2004-02-13 Sanofi Synthelabo Derives de 5-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, leur preparation et leur application en therapeutique
EP2344636B1 (en) * 2008-10-09 2017-12-06 Howard Hughes Medical Institute Novel chimeric ligand-gated ion channels and methods of use thereof
US20110262407A1 (en) * 2008-11-11 2011-10-27 Targacept, Inc. Treatment with alpha7 selective ligands
KR101928505B1 (ko) * 2011-01-28 2018-12-12 에스케이바이오팜 주식회사 피리돈 유도체 및 이를 포함하는 약학적 조성물

Also Published As

Publication number Publication date
EP2668186B1 (en) 2017-05-03
KR101925971B1 (ko) 2018-12-06
EP2668186A1 (en) 2013-12-04
US20130317059A1 (en) 2013-11-28
JP2014503599A (ja) 2014-02-13
CN103328477B (zh) 2016-01-20
CA2824467C (en) 2019-07-02
US8716309B2 (en) 2014-05-06
KR20120087852A (ko) 2012-08-07
CN103328477A (zh) 2013-09-25
JP5921576B2 (ja) 2016-05-24
EP2668186A4 (en) 2014-03-19
CA2824467A1 (en) 2012-08-02
WO2012102580A1 (en) 2012-08-02

Similar Documents

Publication Publication Date Title
ES2634204T3 (es) Composición farmacéutica que comprende derivados de piridona
Kryshchyshyn et al. Thiazolidinone/thiazole based hybrids–New class of antitrypanosomal agents
US9061966B2 (en) Cyclopropylamine inhibitors of oxidases
CO6361928A2 (es) Modulares de aril metil benzoquinazolinona alostericos positivos del receptor m1
ES2872335T3 (es) Derivados de 2,4-tiazolidindiona en el tratamiento de trastornos del sistema nervioso central
ES2353093B1 (es) Uso de derivados de quinazolinas y sus composiciones farmacéuticas en enfermedades neurodegenerativas.
ES2685923T3 (es) Composición medicinal para mejorar la función cerebral
AU2017207991A1 (en) Pyridazine derivatives as EAAT2 activators
ATE453617T1 (de) Substituierte n-arylbenzamide und verwandte verbindungen zur behandlung von amyloidkrankheiten und synukleinopathien
US11427590B2 (en) Small molecule inhibitors of neutral sphingomyelinase 2 (nSMase2) for the treatment of neurodegenerative diseases
CA2641790A1 (en) Ubiquitin/proteasome inhibitors for the treatment of spinal muscular atrophy
US11377452B2 (en) Glutamate transporter activators and methods using same
UY29823A1 (es) Derivados sustituidos de 7-cloro-3h-imidazol-(4,5-b) piridina, composiciones farmacéuticas que los contienen, procesos para la preparación de los mismos y aplicaciones
ES2272911T3 (es) Uso de derivados de fenotiazina piperazina en la fabricacion de un medicamento con efectos neuroprotector y/o neurotroficos sobre cns y/o pns.
ES2321526T3 (es) Utilizacion de epotilones en el tratamiento de defetos de conectividad neuronal tales como la esquizofrenia y el autismo.
US20180289655A1 (en) Methods and Compositions for the Intravenous Administration of Fumarates for the Treatment of Neurological Diseases
US20060281720A1 (en) 5-Androstenediol As An Inhibitor of Gliomas
KR20260009855A (ko) 운동 장애를 치료하기 위한 치료 방법 및 조성물
WO2024040155A1 (en) Isoxazolidines as ripk1 inhibitors and use thereof
CN116987091A (zh) 用于治疗癫痫发作疾病的药物及其制备方法
JP2024520758A (ja) Ｔｔｂｋ１の阻害剤
JP6108423B2 (ja) ［２．２．２］二環式誘導体及び使用方法
CN119497710A (zh) 喹喔啉二酮和吡啶并[2,3-b]吡嗪-2,3-二酮b细胞淋巴瘤6(bcl6)降解剂及其用途
WO2009140483A1 (en) Muscarinic agonists as cognitive enhancers
EP3768681A1 (en) INHIBITION OF nSMase FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS INFECTION